Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

A study in weight loss drugs where one third of participants were given a placebo turned out to have some impressive results.

LOOKING at my reflection in the mirror, I felt delighted to see my petite size 8 figure once again. But as I glanced up to my face, the gaunt woman staring back at me came as a shock. After having ...

Can you get addicted to weight loss? You most certainly can - and recently, colleagues and I have noticed a surge in patients ...

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...

When public figures who championed body positivity lose weight, it can feel personal. Here's why, and what to do with those ...

We are just starting to learn more about the systemic impact of these medications,” Dr. Shiara Ortiz-Pujols told The Post.

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...

GLP-1 drugs like Ozempic are revolutionizing diabetes care. But they’re also making users less likely to drink alcohol. That ...

Novo Nordisk continues to deliver strong revenue, profit growth, and high economic profitability. Read why I rate NVO stock a ...

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels ...